The Buck Institute, Juvenescence, and Insilico Medicine have announced a research collaboration utilizing artificial intelligence (AI) to discover and develop novel anti-aging therapeutics targeting a new molecular pathway.

The three organizations have announced the formation of Napa Therapeutics, Ltd, a company that would commercialize the results of the research collaboration. The collaboration will utilize an end-to-end machine learning system to identify the molecular targets and generate the novel compounds.

The Buck Institute is one of the leading research centres in the world focused solely on research on aging and the elimination of age-related disease. Insilico Medicine is an AI company focused on a range of verticals devoted to aging. Insilico Medicine stands to earn more than $100 million in milestone payments should the program be successful. Juvenescence is a company focused on developing drugs to modify aging and the diseases of aging.